We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE Collaborates With NVIDIA for AI in Healthcare Products
Read MoreHide Full Article
General Electric Company (GE - Free Report) recently collaborated with visual computing firm NVIDIA Corporation (NVDA - Free Report) to incorporate state-of-the-art artificial intelligence (AI) in its healthcare imaging devices. The strategic deal will provide the industrial goods manufacturer an edge over its peers and augment its position in the market.
AI is the simulation of human intelligence in machines. With an increasingly competitive market, manufacturers aim to develop sophisticated products by integrating AI in machines to improve the efficiency and accuracy levels. The advent of data analytics has further enhanced the scope of using AI in machines and has improved the interoperability of products.
GE intends to leverage NVIDIA’s AI computing platform to develop Revolution Frontier CT — an advanced CT scan instrument — that is two times faster than the existing products available in the market. Cleared by the FDA, it is likely to offer superior clinical outcomes in liver lesion detection and kidney lesion. This would ultimately benefit patients with compromised renal function by eliminating unnecessary follow-ups and doctor visits.
It has been reportedly found that less than 3% of more than 50 petabytes of data generated on an average by hospitals is tagged or analyzed. GE Healthcare aims to harness this data for improved patient outcome by combining AI into its medical devices. This is likely to augment its revenues with ease of use and higher clinical efficiency.
Shares of GE have underperformed the industry year to date, with an average loss of 42.5% compared with a decline of 5.7% for the latter. In order to boost the company’s sagging shares, CEO John Flannery has decided to focus on just three core segments — power, aviation and health-care equipment — and gradually exit all other businesses. GE further intends to sell assets worth $20 billion to improve its liquidity. The collaboration with NVIDA is a step in this regard.
Danaher has a long-term earnings growth expectation of 10.6%. It has surpassed estimates in each of the trailing four quarters with an average positive surprise of 2.6%.
Leucadia has an expected long-term earnings growth rate of 18%. It has exceeded estimates thrice in the trailing four quarters with an average beat of 21.2%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
GE Collaborates With NVIDIA for AI in Healthcare Products
General Electric Company (GE - Free Report) recently collaborated with visual computing firm NVIDIA Corporation (NVDA - Free Report) to incorporate state-of-the-art artificial intelligence (AI) in its healthcare imaging devices. The strategic deal will provide the industrial goods manufacturer an edge over its peers and augment its position in the market.
AI is the simulation of human intelligence in machines. With an increasingly competitive market, manufacturers aim to develop sophisticated products by integrating AI in machines to improve the efficiency and accuracy levels. The advent of data analytics has further enhanced the scope of using AI in machines and has improved the interoperability of products.
GE intends to leverage NVIDIA’s AI computing platform to develop Revolution Frontier CT — an advanced CT scan instrument — that is two times faster than the existing products available in the market. Cleared by the FDA, it is likely to offer superior clinical outcomes in liver lesion detection and kidney lesion. This would ultimately benefit patients with compromised renal function by eliminating unnecessary follow-ups and doctor visits.
It has been reportedly found that less than 3% of more than 50 petabytes of data generated on an average by hospitals is tagged or analyzed. GE Healthcare aims to harness this data for improved patient outcome by combining AI into its medical devices. This is likely to augment its revenues with ease of use and higher clinical efficiency.
Shares of GE have underperformed the industry year to date, with an average loss of 42.5% compared with a decline of 5.7% for the latter. In order to boost the company’s sagging shares, CEO John Flannery has decided to focus on just three core segments — power, aviation and health-care equipment — and gradually exit all other businesses. GE further intends to sell assets worth $20 billion to improve its liquidity. The collaboration with NVIDA is a step in this regard.
GE currently has a Zacks Rank #5 (Strong Sell). Better-ranked stocks in the industry include Danaher Corporation (DHR - Free Report) and Leucadia National Corporation , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Danaher has a long-term earnings growth expectation of 10.6%. It has surpassed estimates in each of the trailing four quarters with an average positive surprise of 2.6%.
Leucadia has an expected long-term earnings growth rate of 18%. It has exceeded estimates thrice in the trailing four quarters with an average beat of 21.2%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>